Trials / Completed
CompletedNCT01213641
Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
An Open-label, Long-term, Prospective, Observational Study to Monitor the Safety and Effectiveness of Ilaris in CAPS Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 288 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this observational study is to collect additional information regarding long-term safety and effectiveness of Ilaris in the treatment of CAPS patients in clinical practice.
Conditions
- Cryopyrin-associated Periodic Syndromes (CAPS)
- Familial Cold Autoinflam Syn (FCAS)
- Muckle-wells Syn (MWS)
- Neonatal Onset Multisystem Inflam Disease (NOMID)
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2015-12-01
- Completion
- 2015-12-01
- First posted
- 2010-10-04
- Last updated
- 2016-03-28
Locations
17 sites across 5 countries: United States, Austria, Germany, Norway, Switzerland
Source: ClinicalTrials.gov record NCT01213641. Inclusion in this directory is not an endorsement.